Local News: Eighty Four, PA 

 | 

Sign Up

 | 

Sign In

Advertisment

Allos Therapeutics

Allos Therapeutics News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Allos Therapeutics News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Allos Therapeutics News

News on Allos Therapeutics continually updated from thousands of sources around the net.

Yesterday | M2.com

News and FDA Updates for Akorn

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Akorn, Oncology

Mon Nov 09, 2009

TheStreet.com

'Mad Money Lightning Round': American Express Clicks

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Monday evening.

Comment?

Related Topix: Mad Money, Entertainment, Television, Financial Markets, Biotech, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Wireless, Telecom, Motorola, Alcon

Fri Nov 06, 2009

Business Wire

Public relations, press release distribution, investor relations, SEC filing

SCOTTSDALE, Ariz.-- --Hypercom Corporation , the high security electronic payment and digital transactions solutions provider, today announced financial results for the third... 11/03/2009 - 04:02 PM Fitch Rates Columbus, Ohio's $279MM GOs 'AAA' CHICAGO-- --Fitch Ratings assigns an 'AAA' rating to the City of Columbus, Ohio's general obligation ...

Comment?

Related Topix: Scottsdale, AZ, Hypercom, Computers, PC Mall, Retail, Construction, Plum Creek Timber Company, Real Estate, Biotech, Medicine, Healthcare Industry, Rehabcare Group

Wed Nov 04, 2009

Denver Business Journal

Allos Therapeutics posts wider Q3 loss on costs as it gears to market cancer drug

Colorado biotech firm Allos Therapeutics Inc. posted a bigger third-quarter loss, citing higher administrative and marketing costs as it gears up to sell its newly approved cancer drug Folotyn.

Comment?

Related Topix: Biotech, Healthcare Industry, Colorado, Marketing, Food and Drug Administration

Mon Oct 26, 2009

Freshnews

Allos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009

Allos Therapeutics, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that Company management will provide a corporate update and review of the third quarter 2009 results via webcast and conference call on Tuesday, November 3, 2009, at 4:30 p.m. ET.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Fri Oct 16, 2009

Denver Post

Colorado Business

Allos Therapeutics Inc. has closed its previously announced public offering of 14 million shares of newly issued common stock at $7.10 per share.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Colorado

Wed Oct 14, 2009

Business Wire

Public relations, press release distribution, investor relations, SEC filing

14 - 15, 2009 at the Javits Convention Center in New York, NY. Content & Communications World breaking news rele... DALLAS & WALL, N.J.-- --AT&T* and Centennial Communications Corp.

Comment?

Related Topix: New York Metro, Wireless, Telecom, Centennial Communications, Startups, Veraz Networks, Mortgage, Personal Finance, Semiconductors, Electronics, Silicon Laboratories, Biotech, Medicine, Healthcare Industry

Tue Oct 13, 2009

JAVA Developer's Journal

ELNK, HERO, ABAT, NTAP, DBRN and ALTH Receives Analytical Coverage from WallStSense.com

Our analysts have issued complimentary analysis on the following six companies: EarthLink Inc.

Comment?

Related Topix: Computers, Network Appliance, North American Scientific, Biotech, Medicine, Medical Equipment, Healthcare Industry, Telecom, IT Services, Electronics, Retail, Apparel, Dress Barn Inc The

Wed Oct 07, 2009

PR-inside.com

Allos Therapeutics Announces Pricing of Public Offering of Common Stock

Allos Therapeutics, Inc. today announced the pricing of an underwritten public offering of 14,000,000 primary shares of its common stock at a public offering price of $7.10 per share.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Investment Banking, Financial Services, Brooklyn, NY, New York, NY, Corporate / Securities Law, Law

Tue Oct 06, 2009

TheStreet.com

Early Movers: Pump Up the Volume

Several small-cap stocks were poised to move on above-average volume during Tuesday's session Extreme Networks tumbled by 38 cents, or 13.2%, to $2.49 in the premarket session after the company on late Monday said fiscal first-quarter net revenue is expected to be approximately $66 million, well below the Thomson Reuters consensus of $80.4 million.

Comment?

Related Topix: Extreme Networks, Telecom, Computers, Biotech, Medicine, Healthcare Industry, Business News

Wed Sep 30, 2009

Fool.com

5 Stocks Approaching Greatness

David Gardner called it. Hea s up 1,334%! See what Davida s recommending that you buy NEXT.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cancer, Lymphoma

Mon Sep 28, 2009

ASHP

FDA Approves Pralatrexate for Treatment of Rare Lymphoma

Pralatrexate, a metabolic inhibitor that resembles folic acid, has been approved for the treatment of peripheral T-cell lymphoma in patients whose disease has returned or not responded to previous therapy, FDA and Allos Therapeutics Inc.

Comment?

Related Topix: Medicine, Folvite, Folic Acid (generic), Medication, Biotech, Healthcare Industry

Sun Sep 27, 2009

Denver Post

Westminster-based Allos gets nod on first cancer drug

Allos Therapeutics said Friday that it has received regulatory approval for its drug to treat a rare form of blood cancer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cancer, Health, Lymphoma, Food and Drug Administration, Oncology

Sat Sep 26, 2009

American Chronicle

News and FDA Updates for Allos Therapeutics

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Medicines Company The, Financial Markets, Opinion

Fri Sep 25, 2009

BioWorld

Allos' Folotyn Wins Accelerated PTCL Nod; More Trials to Come

Even as Allos Therapeutics Inc. prepares for the commercial launch of Folotyn in relapsed, refractory peripheral T-cell lymphoma following accelerated FDA approval, the Westminster, Colo.-based firm already has its sights set on expanding the targeted antifolate drug into broader the T-cell lymphoma space and other cancer indications.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Lymphoma, Health, Food and Drug Administration, Cancer, 9

The South Mississippi Sun Herald

FDA Approves Pralatrexate for Treatment of Peripheral T-Cell...

MENLO PARK, Calif., NEW YORK and BIRMINGHAM, Ala., Sept. 25 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma .

Comment?

Related Topix: Food and Drug Administration, Medicine, Hospital Administration, Healthcare Industry, Technical Services, Biotech

Earth Times

Allos Therapeuticsa FOLOTYNa First and Only FDA-Approved Therapy for...

Allos Therapeutics, Inc. today announced that last night the U.S. Food and Drug Administration granted accelerated approval for FOLOTYNTM for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma .

Comment?

Related Topix: Biotech, Healthcare Law, Medicine, Law, Healthcare Industry, Food and Drug Administration

Thu Sep 24, 2009

Zacks Analyst Blog

Testing Time for Allos

We are awaiting the US Food and Drug Administration's decision regarding Allos Therapeutics ' lymphoma drug Folotyn.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Lymphoma

Wed Sep 23, 2009

TheStreet.com

'Mad Money Lightning Round': Bank on Toronto-Dominion

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Tuesday evening.

Comment?

Related Topix: Mad Money, Entertainment, Television, Financial Markets, Biotech, Medicine, Healthcare Industry, Telecom, Tellabs, Cable & Satellite, Alaska Communications Systems Group, TheStreetcom, Media, Computers

Mon Sep 21, 2009

The Denver Business Journal

Dow down Monday, but NASDAQ up

The Dow opened the week down 41 points Monday, while the NASDAQ composite rose. In Colorado, Allos Therapeutics was among the few actively traded gainers, while Delta Petroleum fell 45 percent on disappointing well-test results.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Delta Petroleum, Energy, Oil & Gas, Financial Markets

Eighty Four Jobs

Also on Topix